369 related articles for article (PubMed ID: 21642865)
1. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
[TBL] [Abstract][Full Text] [Related]
2. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Sun JM; Han J; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.
Shaw AT; Varghese AM; Solomon BJ; Costa DB; Novello S; Mino-Kenudson M; Awad MM; Engelman JA; Riely GJ; Monica V; Yeap BY; Scagliotti GV
Ann Oncol; 2013 Jan; 24(1):59-66. PubMed ID: 22887466
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
[TBL] [Abstract][Full Text] [Related]
5. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer.
Lee HY; Ahn HK; Jeong JY; Kwon MJ; Han JH; Sun JM; Ahn JS; Park K; Choi YL; Ahn MJ
Lung Cancer; 2013 Jan; 79(1):40-5. PubMed ID: 23103072
[TBL] [Abstract][Full Text] [Related]
6. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
8. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
Liang Y; Wakelee HA; Neal JW
Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
[TBL] [Abstract][Full Text] [Related]
9. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
Lee JK; Park HS; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS; Kim WH; Bang YJ
Cancer; 2012 Jul; 118(14):3579-86. PubMed ID: 22086654
[TBL] [Abstract][Full Text] [Related]
10. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
[TBL] [Abstract][Full Text] [Related]
11. Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.
Christoph DC; Reyna-Asuncion B; Hassan B; Tran C; Maltzman JD; O'Shannessy DJ; Gauler TC; Wohlschlaeger J; Schuler M; Eberhardt WE; Hirsch FR
Clin Lung Cancer; 2014 Sep; 15(5):320-30.e1-3. PubMed ID: 24993594
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.
Jo J; Kim SH; Kim YJ; Lee J; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Chung JH; Jeon YK; Lee JS
Yonsei Med J; 2018 Mar; 59(2):202-210. PubMed ID: 29436187
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
Koh Y; Kim DW; Kim TM; Lee SH; Jeon YK; Chung DH; Kim YW; Heo DS; Kim WH; Bang YJ
J Thorac Oncol; 2011 May; 6(5):905-12. PubMed ID: 21358343
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
[TBL] [Abstract][Full Text] [Related]
18. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
Hainsworth JD; Cebotaru CL; Kanarev V; Ciuleanu TE; Damyanov D; Stella P; Ganchev H; Pover G; Morris C; Tzekova V
J Thorac Oncol; 2010 Oct; 5(10):1630-6. PubMed ID: 20802351
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.
Kawano Y; Ohyanagi F; Yanagitani N; Kudo K; Horiike A; Tanimoto A; Nishizawa H; Ichikawa A; Sakatani T; Nakatomi K; Hagiwara S; Ninomiya H; Motoi N; Ishikawa Y; Horai T; Nishio M
Anticancer Res; 2013 Aug; 33(8):3327-33. PubMed ID: 23898099
[TBL] [Abstract][Full Text] [Related]
20. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
